Welcome to our dedicated page for GeoVax Labs Warrants news (Ticker: GOVXW), a resource for investors and traders seeking the latest updates and insights on GeoVax Labs Warrants stock.
GeoVax Labs, Inc. (OTCQB: GOVX) is a clinical-stage biotechnology company specializing in developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers.
Utilizing novel proprietary platforms like the modified vaccinia ankara - virus-like particle (MVA-VLP) vaccine platform, GeoVax's pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and gene-directed therapy for head and neck cancers.
Additional research programs focus on preventive vaccines against infectious diseases like Monkeypox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, along with immunotherapies for various solid tumors.
Recent achievements include positive initial safety and immune response findings from a Phase 2 clinical trial evaluating GEO-CM04S1, the COVID-19 vaccine, as a heterologous booster in 63 healthy adults who previously received the Pfizer or Moderna mRNA vaccine. The trial has demonstrated statistically significant increases in neutralizing antibody responses against multiple SARS-CoV-2 variants.
GeoVax Labs (GOVX) reported its financial results for Q2 2022, revealing a net loss of $2.2 million ($0.21 per share), compared to a loss of $1.3 million ($0.18 per share) in Q2 2021. The company is advancing its Phase 2 clinical trials for its COVID-19 vaccine, GEO-CM04S1, targeting immunocompromised cancer patients. Cash balances increased to $30.9 million following fundraises of $18.5 million in May and $9.2 million in January. With these resources, GeoVax is focused on accelerating clinical trials and enhancing its pipeline in vaccines and immunotherapies.
GeoVax Labs (GOVX) announced the publication of a peer-reviewed animal efficacy study for its MVA-VLP-SUDV vaccine against Sudan ebolavirus, published in Nature Partner Journals Vaccines. The study demonstrated that guinea pigs vaccinated with one or two doses generated strong immune responses, achieving 100% protection against SUDV post-exposure. The vaccine integrates live attenuated vector advantages with virus-like particle technology, facilitating emergency responses. The company aims to initiate nonhuman primate trials soon, further validating its vaccine platform.
GeoVax Labs, a biotechnology company focused on vaccines and immunotherapies, will report its second quarter 2022 financial results on August 3, 2022, after market close. A conference call is scheduled for the same day at 4:30 p.m. ET, where management will discuss financials and corporate developments. The company is advancing two Phase 2 trials for its COVID-19 booster vaccine and developing a pan-coronavirus vaccine. They also have ongoing trials for Gedeptin®, an orphan drug for head and neck cancer, among other projects.
GeoVax Labs, Inc. (Nasdaq: GOVX) has appointed Dr. John W. Sharkey as Vice President of Business Development, effective June 13, 2022. With over 30 years in the pharmaceutical and medical device sectors, Dr. Sharkey previously served as the company’s Head of Business Development and successfully guided key transactions that advanced GeoVax into Phase 2 clinical trials for COVID-19 and Immuno-Oncology. His extensive experience includes executive roles at Novartis and Shionogi, emphasizing business growth and product development.
GeoVax Labs, Inc. (Nasdaq: GOVX) announced that its Chairman & CEO, David Dodd, will present at the BIO International Convention 2022 in San Diego from June 13-16. His presentation is scheduled for June 15 at 11:30 a.m. PT in Theater 4. The company will discuss its Phase 2 clinical trials for the COVID-19 vaccine GEO-CM04S1 and Gedeptin®, an innovative cancer treatment. Management will also host one-on-one meetings to explore strategic partnerships. GeoVax specializes in vaccines and immunotherapies for infectious diseases and cancer.
GeoVax Labs, Inc. (GOVX) announced a definitive agreement to issue and sell 3,030,304 shares at $1.65 per share in a registered direct offering, alongside a private placement of 9,090,910 shares at the same price. The total gross proceeds from both offerings are projected to be approximately $20 million. Closing is expected on or about May 27, 2022. The unregistered investment options, exercisable at $1.65 per share, will expire in five to six years. H.C. Wainwright & Co. acts as the exclusive placement agent for these offerings.
GeoVax Labs, Inc. (GOVX) has announced a Notice of Allowance from the Chinese Patent Office for its patent titled "Compositions and Methods for Generating an Immune Response to a Tumor Associated Antigen." This patent supports the company's GV-MVA-VLP™ vaccine platform, which aims to treat various cancers using the MUC1 antigen. GeoVax has commenced IND-enabling animal studies to establish protocols for Phase 1 clinical trials. David Dodd, CEO, emphasized the growing patent portfolio of over 70 applications, highlighting the company's commitment to advancing cancer immunotherapies.
GeoVax Labs, Inc. (Nasdaq: GOVX) announced its participation in key scientific conferences showcasing advancements in vaccine development. Notable presentations include:
- National Biotechnology Conference: Dr. Mary Hauser will discuss T cell immunity against evolving SARS-CoV-2 variants on May 11, 2022.
- Genetic Vaccine Development Summit: Dr. Don Diamond will present on the COH04S1 vaccine's development on May 26, 2022.
GeoVax is advancing COVID-19 and cancer immunotherapies, with ongoing Phase 2 trials and innovative vaccine platforms.
GeoVax Labs (GOVX) reported its financial results for Q1 2022, showing a net loss of $2.4 million, up from $1.6 million a year prior. The company is advancing Phase 2 clinical trials for the COVID-19 vaccine GEO-CM04S1, which targets both spike and nucleocapsid proteins. In addition, it is conducting a Phase 1/2 trial for Gedeptin® in head and neck cancer. The company strengthened its operational resources and has $16.3 million in cash as of March 31, 2022, following a $9.2 million private placement.
GeoVax Labs (Nasdaq: GOVX) announced the issuance of U.S. Patent No. 11,311,612 for its multi-antigenic malaria vaccine approach, seeking to improve immune responses against malaria, which causes 228 million infections annually. Unlike traditional vaccines targeting single stages of the parasite, GeoVax’s MVA-VLP candidates address multiple stages, fostering durable T cell and antibody responses. CEO David Dodd emphasized the company's commitment to public health innovation, focusing on malaria alongside ongoing COVID-19 and cancer immunotherapy programs.
FAQ
What is the current stock price of GeoVax Labs Warrants (GOVXW)?
What is GeoVax Labs, Inc. focused on developing?
What recent achievements has GeoVax Labs, Inc. made?
Which diseases are targeted by GeoVax's vaccine development programs?
